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Abstract   
 
RalA and RalB are members of the Ras family of small G proteins and are activated downstream 
of Ras via RalGEFs. The RalGEF-Ral axis represents one of the major effector pathways 
controlled by Ras and as such is an important pharmacological target. RalA and RalB are 
approximately 80% identical at the amino acid level; despite this they have distinct roles both in 
normal cells and in the disease state. We have used our structure of RalB-RLIP76 to guide an 
analysis of Ral-effector interaction interfaces, creating panels of mutant proteins to probe the 
energetics of these interactions. The data provide a physical mechanism that underpins the effector 
selective mutations commonly employed to dissect Ral G protein function. Comparing the 
energetic landscape of the RalB-RLIP76 and RalB-Sec5 complexes reveals mutations in RalB that 
differentially bind the two effector proteins. A panel of RLIP76 mutants was used to probe the 
interaction between RLIP76 and RalA/B. Despite 100% sequence identity in the RalA/B contact 
residues with RLIP76, differences still exist in the energetic profiles of the two complexes. 
Therefore we have revealed properties that may account for some of the functional separation 
observed with RalA and RalB at a cellular level. Our mutations, in both the Ral isoforms and 
RLIP76, provide new tools that can be employed to parse the complex biology of Ral G protein 
signalling networks. The combination of this thermodynamic and structural data can also guide 
efforts to ablate RalA/B activity with small molecules and peptides. 
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The Ral proteins are small G proteins that are activated downstream of Ras. There are two human 
Ral proteins, RalA and RalB, which despite having 82% sequence identity at the amino acid level 
have distinct cellular functions. Both proteins have roles in the regulation of cytokinesis. RalA acts 
first to secure the exocyst complex to the cytokinetic furrow; this is followed by RalB activity, 
which engages the exocyst at the midbody of the cytoplasmic bridge to drive abscission
1
. RalB has 
been demonstrated to promote autophagocytosis
2
, while RalA controls mitochondrial fission at 
mitosis
3
. Both Ral proteins also have roles in targeted exocytosis, receptor mediated endocytosis 
and the regulation of the actin cytoskeleton and while individual roles have not been assigned to 
RalA and RalB in these processes, it seems likely they will emerge. In fact some specific roles are 
already known, for example, RalA drives polarized exocytosis in epithelial cells
4
, whereas RalB 
controls exocytosis during polarized cell migration
5
. Distinctive roles have also been assigned to 
RalA and RalB in the disease state: RalA is required for anchorage-independent proliferation in 
cancer cell lines, while RalB is necessary for tumour cells to avoid apoptosis
6
. 
 
In common with most other small G proteins, the Ral proteins are found in two forms. When 
bound to GDP, they are inactive but when bound to GTP, they adopt their active conformation and 
can engage with downstream effector proteins, initiate signalling cascades and control cellular 
outcomes. The functional individuality of RalA and RalB is even more surprising considering they 
interact with the same set of downstream effector proteins and therefore share control of the same 
collection of signalling pathways
7
. Proposals for the mechanism underlying the specific actions of 
the Ral proteins in the absence of differential sets of effector proteins include distinctive cellular 
localization and divergent activation. The active conformation of small G proteins is based around 
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two regions of the protein, known as switch 1 and switch 2, which are sensitive to the presence of 
the terminal phosphate in GTP. These switch regions mediate the majority of contacts with the 
effector proteins. RalA and RalB are identical in the switch regions, and most of the variation 
between the two proteins lies at their C-termini, beyond the structured G domain, in the residues 
that comprise the ‘hypervariable region’8. In most small G proteins, this region controls membrane 
localization
9
. Both proteins have been observed localized at the plasma membrane and also at 
endomembranes. RalA and RalB are geranylgeranylated at Cys203, which constitutes the primary 
membrane attachment cue and both contain multiple positively charged sidechains preceding this 
that could act as secondary membrane localization signals. Both proteins also carry 
phosphorylation sites in this region. RalA is phosphorylated at Ser183 and Ser194: pSer194 is a 
consequence of Aurora A activity and results in translocation of RalA to mitochondria
3
. RalB is 
phosphorylated by PKC on Ser198; the outcome of this is relocation to endomembranes
10
. Specific 
membrane localization could result in the Ral proteins encountering subsets of effector proteins 
and therefore activating specific signalling pathways. Likewise, specificity could also come via 
distinct actuation signals and activators. Ral proteins are activated by RalGEFs, some of which 
provide the direct link to Ras signalling. However there are currently six GEFs that have been 
identified for the Ral proteins
7
. In the case of cytokinesis, the distinct roles for RalA and RalB are 
designated by individual pairs of RalGEFs, which coordinate several input signals
1
. 
 
Several effector proteins have been identified for RalA and RalB. The first one to be identified was 
RLIP76 (also known as RalBP1 and RIP1
11-13
). RLIP76 appears to play multiple, disparate roles in 
Ral signalling
7
. Alongside RLIP76, two components of the exocyst complex, Sec5 and Exo84 are 
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the best-characterized effector proteins for the Ral proteins. Through these effectors the Ral 
proteins control polarized exocytosis
14
 but also non-exocyst functions including activation of 
TBK1
15
 and autophagosome assembly
2
. Ral proteins are also known to interact with ZONAB, a 
transcription regulator
16
, and filamin, the actin crosslinking protein
17
. Interestingly, the Ral 
proteins also seem to interact with phospholipase D and phospholipase C-1 but in a nucleotide-
independent manner
18, 19
. The latter four interactions are not as well characterized. There is some 
evidence that RalA and RalB do have differential affinity for their effector proteins
4
 and this would 
certainly contribute to conferring specific cellular roles to the proteins. 
 
We have previously solved the structure of the complex that forms between RalB and the RLIP76 
RBD
20
. We have now used this structure to design mutants of both RalB and RLIP76 to elucidate 
the thermodynamics of the binding interface produced by the two proteins interacting. In addition, 
we have used the panel of RalB mutants that we generated to probe the interaction between RalB 
and a second effector protein, Sec5. Comparing the energetic landscape of the two complexes has 
revealed mutations in RalB that differentially bind the two effector proteins. We have also used the 
RLIP76 mutants to probe the interaction between RLIP76 and RalA to compare the energetics of 
the RalA and RalB complexes. Despite 100% sequence identity in the RalA/B contact residues for 
RLIP76, differences still exist in the energetic profiles of the two complexes.  
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Methods 
Protein Expression Constructs 
Simian RalA C (residues 1-184) was amplified by PCR and cloned into pMAT10 (DO, 
unpublished) using BamHI and EcoRI sites that had been incorporated into the PCR primers. The 
resulting construct expresses RalA as an N-terminal His-MBP fusion protein with a thrombin 
cleavable tag. Full-length Simian RalA (residues 1-206) was amplified by PCR and cloned into 
pGEX-6P (GE Healthcare) using BamHI and EcoRI sites that had been incorporated into the PCR 
primers. RalB C (residues 1-185) was cloned into pET16b using NdeI and BamHI sites that had 
been incorporated into the PCR primers. Full-length Human RalB (residues 1-206) was amplified 
by PCR and cloned into pMAT10P (DO, unpublished) using BamHI and EcoRI sites that had been 
incorporated into the PCR primers. The resulting construct expresses RalB as an N-terminal His-
MBP fusion protein with the tag cleavable using PreScission protease.  All Ral expression 
constructs incorporate the activating mutation Q72L and were expressed in E. coli BL21(DE3) 
(Invitrogen).   
 
The RBD of human RLIP76 (393-446) was cloned into a modified version of pGEX-His-2
21
. A 
thrombin cleavage site was engineered into pGEX-His-2, 5' to the BamHI cloning site. RLIP76 
(393-446) was amplified by PCR and cloned into modified pGEX-His-2 using BamHI and XhoI 
restriction sites that had been incorporated into the PCR primers. The resulting construct expressed 
GST-RLIP76 RBD with a C-terminal His tag. The C411S mutation was introduced as described 
below. The construct was expressed in E. coli BL21 (Invitrogen). The Sec5 RBD expression 
construct has been described elsewhere
22
. 
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Recombinant Protein Production 
A stationary culture containing pMAT10-RalA C was diluted 1 in 10 into 2TY and grown to an 
A600 of ~0.8 at 37 °C, induced with 1mM IPTG and grown for a further 16 h at 20°C. Cells were 
lysed and the fusion protein purified using Ni-NTA resin (Qiagen) following manufacturer’s 
instructions. The fusion protein was cleaved with thrombin to remove the His-MBP tag. A 
stationary culture containing pGEX-6P-full-length RalA was diluted 1 in 10 into 2TY and grown 
to an A600 of ~0.8 at 37 °C, induced with 0.1mM IPTG and grown for a further 5 h at 37°C. Cells 
were lysed and the fusion protein purified using glutathione-agarose resin (Sigma-Aldrich) 
following manufacturer’s instructions. The fusion protein was cleaved with PreScission protease to 
remove the GST tag. A stationary culture containing pET16b-RalB was diluted 1 in 10 into 2TY 
and grown to an A600 of ~0.8 at 37 °C, induced with 1mM IPTG and grown for a further 3h at 
37°C. Cells were lysed and the fusion protein purified using Ni-NTA resin (Qiagen) as above. The 
fusion protein was cleaved with Factor Xa (Roche) to remove the His tag. A stationary culture 
containing pMAT10P-full-length RalB was diluted 1 in 10 into 2TY and grown to an A600 of ~0.8 
at 37 °C, induced with 1mM IPTG and grown for a further 16 h at 20°C. Cells were lysed and the 
fusion protein purified using Ni-NTA resin (Qiagen) as above. The fusion protein was cleaved 
with PreScission protease to remove the His-MBP tag. All Ral proteins were further purified by 
gel filtration (S75 16/60, GE Healthcare). 
 
A stationary culture of each RLIP76 RBD construct was diluted 1 in 10 into 2TY, grown to an A600 
of ~0.8 at 37 °C, induced with 0.1mM IPTG and grown for a further 5h at 37 °C. Cells were lysed 
 9 
and the fusion protein purified using glutathione agarose (Sigma-Aldrich) following 
manufacturer’s instructions. The fusion protein was cleaved with thrombin to remove the GST tag 
and further purified by gel filtration (S30 16/60, GE Healthcare). An accurate concentration of 
each protein was determined using amino acid analysis by the Protein and Nucleic Acid Chemistry 
Facility, Dept. Biochemistry, University of Cambridge. This protein was then used directly in 
SPAs. Purification of the Sec5 RBD has been published previously
22
. 
 
Mutagenesis of the RLIP76 RBD 
Mutations were introduced, as specified, into the coding region of RLIP76 RBD using the 
QuikChange Lightning Multi Site Directed Mutagenesis Kit (Agilent) following manufacturer’s 
instructions. The sequences of the coding regions of all mutants were verified by the DNA 
Sequencing Facility, Department of Biochemistry, University of Cambridge.  
 
Nucleotide Exchange 
Ral proteins were labelled with [
3
H]GTP for use in binding assays as described previously
22
. 
 
Scintillation Proximity Assays (SPA) 
Affinities of Ral proteins for the RLIP76 RBD-His domain and its variants were measured using 
SPA. 80 nM of RLIP76 RBD-His variants were immobilised on Protein A SPA 
fluoromicrospheres via an anti-His antibody (Sigma-Aldrich). 20 nM GST-Sec5 was immobilized 
via an anti-GST antibody as described previously
22
. The equilibrium binding constants (Kd) of the 
effector-G protein interaction were determined by monitoring the SPA signal in the presence of 
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varying concentrations of [
3
H]GTP·Ral,  as described previously
23
. Binding of Ral to the effector 
protein brings the radiolabelled nucleotide close enough to the scintillant to obtain a signal. For 
each Ral protein, an experiment was performed in the absence of effector, which resulted in a 
linear increase in background SPA counts. This data set was then subtracted from the data points 
obtained in the presence of effector and plotted as a function of increasing concentration of Ral 
protein.  For each affinity determination, data points were obtained for at least 10 different G 
protein concentrations. Binding curves were fitted using a direct binding isotherm 
23
 to obtain Kd 
values and their standard errors for the G protein-effector interactions.
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Results 
Binding affinity of RLIP76 RBD for Ral isoforms 
Previously we had measured the affinity of the RLIP76 RBD for both RalA and RalB and found 
that the two Ral isoforms interacted with similar affinities (our unpublished data and
20
). We 
described a similar situation with another Ral effector, Sec5
22
. For practical reasons, these 
measurements had been undertaken with RalA 1-206 (full-length) and RalB 1-185 (C-terminal 
truncation). This prompted us to investigate the binding affinities of full-length and truncated RalA 
and truncated RalB for the RLIP76 RBD, along with the RBD of a second Ral effector, Sec5 for 
comparison. The apparent Kd values for the interaction between the Ral variants and the RLIP76 
RBD were determined by SPA. The binding isotherms are shown in Figure 1 and the affinities are 
summarized in Table 1. Full-length RalA binds RLIP76 RBD with a Kd of 324 ± 22nM, while 
RalA C binds with a Kd of 264 ± 16 nM. RalB C binds with a Kd of 209 ± 14 nM. Despite 
repeated attempts, we were unable to purify sufficiently high quality full-length RalB to perform 
equivalent experiments with this variant. Full-length RalA binds Sec5 RBD with a Kd of 121 ± 
13nM, while RalA C binds with a Kd of 192 ± 15 nM. RalB C binds with a Kd of 135 ± 9 nM. 
The C-terminal tail of the Ral proteins, as with most small G proteins, is thought to direct 
membrane localization in the cell. As such it is usually unavailable for effector binding, although 
we have previously identified a role for the C-terminal polybasic region from one small G protein 
(Rac1) in effector binding
24
. These data indicate that full-length RalA and RalA C bind with 
equivalent affinity to RLIP 76 and Sec5. RalA C and RalB C also bind with similar affinities to 
each effector protein. We decided to proceed with a comparative study of RalA C and RalB C 
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binding to RLIP76 to look for thermodynamic differences in the two Ral-RLIP76 complexes.  
 
Thermodynamic mapping of the RLIP76 and Sec5 binding surfaces on RalB 
The structures of Ral proteins in complex with the RLIP76 and Sec5 Ral binding domains
25, 26
 
provided the starting points for mapping the energetics of the interface between RalB and these 
effectors. We analysed the interfaces of the complexes (PDB codes 1UAD and 2KWI) to identify 
residues on the small G protein that were within 4Å of an effector residue and mutated these to 
alanine in RalB. There are two sidechains in RalB that interact with these effectors that are already 
alanine: Ala48 and Ala77. Ala48 contacts both RLIP76 and Sec5 and was changed to Gly, so that 
the requirement for the alanine methyl group could be probed. Ala48 lies within switch 1, which is 
unstructured and highly flexible in active RalB, so substitution with a glycine is unlikely to affect 
the secondary structure. Ala77 is within a helix in switch 2 in RalB and interacts with His413 and 
various hydrophobic residues in RLIP76. We therefore mutated it to a larger, charged residue 
(Arg). Other mutations were also made as follows. Tyr36 forms a hydrogen bond in both Sec5 and 
RLIP76 complexes, so we mutated it to Phe, reasoning that this would remove the hydroxyl group, 
while maintaining the bulky aromatic ring. Glu38 forms a salt bridge with Arg27 in the Sec5 
complex, so we mutated it to Gln, hence removing the charge but maintaining the size of the 
sidechain. Two mutations were made to Thr46, although this residue does not interact directly with 
either effector. Thr46 is equivalent to Ras Thr35, whose mutation to Ser prevented Ras binding to 
RalGDS and PI3K but not to Raf
27, 28
. The T46S mutant is the direct equivalent and was tested to 
investigate whether this mutation would discriminate between RLIP76 and Sec5. The T46A 
mutation was also generated, to study the effect of removing the hydroxyl group completely. 
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Finally, the D49E mutation was generated because this is mutant is known to prevent binding to 
Sec5 but not to RLIP76 in yeast two-hybrid experiments
29
. This therefore allowed an assessment 
of whether the in vitro affinity measurements correlate with the effects of this mutation in a (yeast) 
cell.  
 
The apparent Kd values for the interaction between the RalB mutants and the RLIP76 and Sec5 
RBDs were determined by SPA. Selected binding isotherms are shown in Figure 2A and 2B and 
the affinities are summarized in Table 2. 
 
Mutations that reduce the binding between RLIP76 RBD and RalB include Y36A, T46A, T46S, 
D49A, Y51A, L67A, Y82A and R84A, which decrease the affinity more than 10-fold, mutations 
E38A and E73A, which decrease the affinity between 5 and 10-fold and mutations E38Q, A48G, 
R52A, I78A and N81A, which all decrease the affinity between 3 and 5-fold.  Interestingly one 
mutation, S50A, shows a small increase in binding affinity for RLIP76. Thus Tyr36, Thr46, 
Asp49, Tyr51, Leu67, Glu73, Tyr82 and Arg84 all contribute at least 1.2kcal/mol to the interface, 
with Tyr51 and Tyr82 making the largest individual contributions.  
 
Mutations Y36A/F, E38A/Q, T46A/S, D49E and Y51A all effectively abrogate binding to Sec5, 
mutations L14A, K47A and L67A all decrease the affinity for Sec5 between 3 and 7-fold. 
Mutations at other residues show only a minor effect or no change in the binding affinity. Mutation 
D49A shows a small increase in binding affinity for Sec5. 
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Thermodynamic mapping of the RalA and RalB binding surfaces on the RLIP76 RBD 
Having investigated the differences in thermodynamics between a Ral protein and two of its 
effector proteins, we next wanted to extend our studies to see if there were any differences in the 
energetic contributions of an effector protein for the two Ral proteins. RalA and RalB have 82% 
sequence identity but are 100% identical across the residues that contact RLIP76
20
 so we next 
investigated the energetic contributions of sidechains on the RLIP76 RBD to binding to the Ral 
small G proteins. In a similar manner to our dissection of the RalB interaction surface, we 
identified sidechains of RLIP76 residues that were within 4Å of a RalB sidechain in our RalB-
RLIP76 RBD structure and mutated them to alanine. The apparent Kd values for the interaction 
between the RLIP76 RBD mutants with RalB were determined by SPA. Selected binding 
isotherms are shown in Figure 3A and the affinities are summarized in Table 3. 
 
Substitution of RLIP76 residues His413, Trp430 and Thr437 with alanine ablated the binding to 
RalB, alanine substitutions of Leu409, Leu429 and Lys440 reduced the affinity significantly (16.5, 
22.8 and 8.8-fold respectively) and substitution of Leu416 with alanine reduced the affinity 4.7-
fold. Mutations at the remaining residues tested had deleterious effects on RalB binding but to a 
lesser extent and were thus considered to be individually insignificant. Exceptionally, introducing 
the Q417A mutation into the RLIP76 RBD enhanced binding to RalB by more than 2-fold. 
 
We then tested the same panel of RLIP76 RBD mutants for their ability to bind RalA. Selected 
binding isotherms are shown in Figure 3B and the affinities are summarized in Table 3. Similarly 
to RalB, mutation to alanine at residues Leu409, His413, Trp430, Thr437 and Lys440 all decrease 
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binding by ~9-fold or more. Mutation at residue Leu416 decreased the affinity 9-fold, which is 
larger than the reduction in affinity for RalB for this mutation, while mutation at Leu429 reduced 
the affinity by 5.6-fold, significantly less than the effect on RalB affinity. Mutating Arg434 to 
alanine abrogated binding to RalA but had very little effect (2-3-fold reduction) on RalB. The 
remaining residues, when mutated, all had a small detrimental affect on binding to RalA and were 
not considered to be significant, except Q433A, which had no affect on RalA binding. There were 
no mutations that increased the binding of RalA. 
 
Residues Leu409, His413, Leu429, Trp430, Thr437 and Lys440 all contribute >1.2 kcal/mol to the 
RLIP76-RalB interface. Residues Leu409, His413, Leu416, Tyr430, Arg434, Thr437 and Lys440 
of RLIP76 all contribute >1.2 kcal/mol to the RLIP76-RalA interface.  
 
Discussion 
Using our structure of RalB bound to the RLIP76 RBD
20
 and the structure of RalA bound to 
Sec5
26
, we have designed mutations to probe the thermodynamics of the binding interfaces and 
dissect the energetic contributions of specific RalB residues for these two effector proteins. Figures 
4A and 4B show heat maps for the RLIP76 and Sec5 binding surfaces on RalB. It is immediately 
striking that the energetically important binding surface for RLIP76 is much more extensive than 
that for Sec5. This is not surprising, since a comparison of the Ral complex structures reveals that 
the effectors themselves are strikingly different, as are the regions that they contact on the Ral 
proteins (Figures 4C and 4D). The Sec5 RBD has an all sheet, Ig-like fold, which forms an 
intermolecular antiparallel  sheet with the 2 strand of RalA, interacting exclusively with residues 
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in and around switch 1 and burying ~1000 Å
2
 in the interface
26
. The RLIP76 RBD-RalB structure
20
 
shows that the RLIP76 RBD forms a simple coiled-coil, which interacts with both switch 1 and 
switch 2 in RalB and buries ~1700 Å
2
. It is logical, therefore that we find residues with significant 
energetic input into RalB-RLIP76 complex formation across RalB switches 1 and 2. For Sec5 the 
highest energetic contributions are exclusively found from residues in switch 1 of RalB. These 
thermodynamic differences highlight certain RalB residues that if mutated would differentially 
discriminate between effectors. For example, RalB Y82A or D49A mutants would no longer bind 
to RLIP76 but would retain the ability to bind to Sec5. Conversely RalB Y36F or D49E should 
retain the ability to bind RLIP76 but no longer be competent to bind Sec5. Such mutations should 
be useful tools to dissect Ral effector pathways in vivo. In fact the affinities of the D49E mutant 
that we have quantified in vitro are in agreement with the results found for this mutation by yeast 
two-hybrid and by co-immunoprecipitation in HEK293T cells
29
. Thus all of the mutants that we 
describe here are likely to have the same effects in vivo as we have seen in vitro. 
 
Some of the residues whose mutation affects binding are not involved in directly contacting the 
effector but play a supporting role in maintaining the structure of the RalB interacting residues. For 
example, in both complexes Thr46 makes no direct contact with the effectors (Figure 4C, 4D) but 
its mutation to Ser or Ala reduces the binding to both significantly. As this Thr residue contacts the 
Mg
2+
 ion in the RalB protein it is not surprising that the integrity of the switch regions is 
compromised. The T46A/S mutants can still, however be loaded with the GTP-analogue and T46S 
shows some affinity for RLIP76. Similarly, Leu67, which is close to the interface in both 
complexes, forms hydrophobic contacts in RLIP76 but not in Sec5. In the latter it still has a small 
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effect on binding, presumably because it supports the RalB 2 strand, which is involved in an 
intermolecular -sheet with Sec5 (Figure 4D). This is also the case for Leu14, which is within 1 
and packs next to Leu67. Leu14 reduces Sec5 binding but not RLIP76 binding, highlighting the 
importance of the intermolecular -sheet in the Sec5 interaction. There are also supporting residues 
in the RalB-RLIP76 interaction whose mutations affect binding. The E38A mutant knocks out 
Sec5 binding and reduces RLIP76 binding. In the Sec5 complex Glu38 forms a salt bridge with 
Sec5 residue Arg27 but Glu38 does not contact RLIP76 directly. Instead, it is likely to be involved 
in maintaining the position of the neighbouring residue, Tyr36, which does contact RLIP76. It is 
possible that replacing the charged Glu38 with the smaller, hydrophobic Ala allows the 1 helix to 
be extended to residue 38, altering its conformation and that of switch 1. This is consistent with the 
observation that the E38Q mutation has a lesser effect on binding of RLIP76, since Gln38 is not 
charged but is more polar than Ala. A similar argument may explain the effect of the E73A mutant, 
which reduces the binding of RLIP76 5-fold. Glu73 is next to the switch 2 helix, 2, and its 
mutation to Ala is likely to alter 2 and therefore the ability of residues in this helix to contact 
RLIP76. 
 
Some of the mutations that we have tested here have previously been generated in RalA and their 
effects on Exo84 and Sec5 measured
30
. The effects on Sec5 binding were broadly consistent with 
our observations on the RalB-Sec5 interaction, for example, the E38A mutation did not affect 
Exo84 binding but reduced the affinity for Sec5 ~45-fold just as in RalB (Table 1). The R52A 
mutant of RalA bound to Sec5, with a similar affinity to wild-type, similar to its effects in RalB, 
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but reduced the affinity of Exo84 18-fold. Arg52 forms a hydrogen bond in the RalA-Exo84 
complex so the effects of this mutation can be explained.  
 
We next resolved the contribution of RLIP76 residues to complex formation with RalA and RalB. 
Figures 5A and 5B show the energetically important residues on RLIP76 for RalA and RalB 
binding. It is striking that although the residues in RalB that contact RLIP76 are 100% conserved 
in RalA, the binding hotspots on RLIP76 are not identical (Table 3):  removal of the Leu412 
sidechain has a small affect on RalA binding but does not change RalB binding; the L429A 
mutation reduces RalA binding less than 6-fold but has a more significant effect on RalB binding 
(23-fold); and R434A in the RLIP76 RBD abrogates binding to RalA completely, while binding to 
RalB is not significantly affected (less than 3-fold).  
 
Leu412 does not directly contact RalB and instead is packed within the RLIP76 coiled-coil directly 
behind Leu429. It is therefore likely that the effects of the L412A mutation are mediated via small 
changes in the orientation of the helices of the coiled-coil, which in turn lead to subtle 
rearrangements of the sidechains that do interact with the RalA molecule. Replacement of Leu412 
with the smaller Ala sidechain would create a cavity inside the coiled coil unless the two helices 
shift closer together. Such a shift would move one of the helices further away from the Ral 
molecule.  
 
Leu429 contacts three residues in RalB switch 2, Ala77, Asn81 and Tyr82, all of which are 
conserved in RalA. Arg434 makes contacts with Lys16 and Asp65, which again are conserved in 
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RalA. Indeed a comparison of all of the differences in sequence between the truncated versions of 
RalA and RalB that were used in this study shows that all of the changes are away from the switch 
regions and the RLIP76 binding site (Figure 5C). The most dramatic difference between RalA and 
RalB lies in the insertion of Ala116 in the loop between helix 3 and strand 5. The same loop is 
also modified by the substitution of the neutral Asn119 in RalA with Lys120 in RalB. These 
changes lead to a different conformation in this loop when RalA and RalB are compared. In both 
Ral proteins, this loop is mobile, exhibiting high temperature factors in the X-ray structures of 
RalA and dynamics on a psec-nsec timescale in RalB
22
. The insertion in the loop is likely to cause 
a subtle shift in the position of the C-terminus of helix 3, which is in direct contact with the 2 
helix at the C-terminus of switch 2 (Figure 5C). Any changes in switch 2 would also be readily 
transmitted to the 1 and 2 strands, which lie underneath switch 2. Hence, the changes in the 3-
5 loop sequence and length may be responsible for the differences in contribution of residues in 
switch 2 (Ala77, Asn81, Tyr82) and the 1/2 strands (Lys16, Asp65) to interactions with RLIP76 
Leu429 and Arg434. For the purposes of this discussion, we have assumed that Leu429 and 
Arg434 contact broadly the same residues in RalA as in RalB, which is likely although not certain 
in the absence of a RalA-RLIP76 structure.    
 
Interestingly substitution of one residue, Gln417, with Ala had little affect on RalA binding but 
slightly increased (2.2-fold) the affinity of the RalB complex. This residue also contacts RalB 
switch 2, via the sidechain of Tyr75. The effects of this mutation therefore also supports the idea 
that switch 2 is subtly different in the RalA and RalB isoforms. This is in agreement with our 
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NMR analysis, which suggests that switch 2 has some differences in msec timescale dynamics in 
the two Ral proteins (manuscript in preparation). 
 
A number of the mutations that we have identified are likely to mediate their effects on binding via 
medium range structural rearrangements. Allostery in GTPases has been observed in several 
situations and its exploitation is becoming increasingly important for targetting these proteins. 
Binding of calcium acetate to helix3-loop7 of Ha-Ras, in a crystallized form, results in structural 
rearrangements that ultimately order the N-terminal region of switch II and position Glu61 in the 
active site
31
. Identification of a unique pocket in the Ki-Ras G12C oncogenic variant prompted 
screening for binding compounds. This pocket is adjacent to the nucleotide binding site and 
binding compounds have been identified that change the nucleotide affinity leading to a preference 
for GDP over GTP and simultaneously block GEF activation using an allosteric mechanism
32
. A 
region adjacent to but distinct from the nucleotide binding site has also been utilized to target 
inhibitors to the Ral GTPases. Again binding to this allosteric site is sufficient to modulate GTPase 
activity in vitro and in vivo
33
. Dynamic exchange between different conformations is also well 
documented in small G proteins. NMR has shown that Ha-Ras bound to GTP or GTP analogues 
exhibits dynamics on a msec timescale
34, 35
. Furthermore, 
31
P NMR experiments suggested the 
presence of multiple conformations in active forms of small GTPases
22, 36
.  Taken together these 
studies demonstrate the importance of conformational and structure flexibility to small G protein 
function and also establish the utility of this feature as a means of attacking these proteins 
therapeutically.  
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In summary, our hotspot analysis of the binding of RLIP76 to RalA and RalB suggests that at least 
some of the differences in the Ral proteins lie in the structure and dynamics of switch 2 and the 
consequences for effector binding that ensue. We have identified some residues of RLIP76 that can 
be mutated to prevent its binding to both RalA and RalB e.g. His413 and Trp430. Furthermore, we 
have identified two residues whose mutation will allow discrimination between the Ral isoforms: 
the L429A mutation will reduce RalB binding significantly more than RalA binding, while the 
R434A mutation abrogates RalA binding but has little effect on RalB binding. These mutants 
represent essential tools for dissecting the roles of RalA and RalB in vivo. 
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Table 1: The affinities of Ral variants for RLIP76 and Sec5 RBDs 
 Apparent Kd (nM)
a 
 RLIP76 RBD Sec5 RBD 
fl RalA, Q72L 324 ± 22 121 ± 13 
RalA C, Q72L 264 ± 16 192 ± 15 
RalB C, Q72L 209 ± 14 135 ± 9 
aEquilibrium binding constants were determined in SPAs as described in the 
Materials and methods. Kd values are quoted with the standard errors from curve 
fitting  
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Table 2: The affinities of RalB mutants for RLI76 RBD and Sec5 RBD 
 RLIP76  Sec5 
RalB Kd (nM)
a G 
(cal/mol) 
G 
(calmol) 
Fold 
Change 
Kd (nM) G 
(cal/mol) 
G 
(calmol) 
Fold 
Change 
Q72L (wt) 216 19 -9088 - - 238  15 -9030 - - 
L14A,Q72L 300  32 -8893 -195 1.4X  1590  112 -7906 -1124 6.7X  
Y36A,Q72L 3040  91 -7522 -1371 10.1X  NB   >50X  
Y36F,Q72L 335  28 -8828 -260 1.5X  7300  1600 -7003 -2027 30.7X  
E38A,Q72L 1390  112b -7986 -1102 6.4X  NB   >50X  
E38Q,Q72L 1050  50.1 -8152 -936 4.9X  4460  506 -7295 -1735 18.7X  
T46A,Q72L NBc   >50X  NB   >50X  
T46S,Q72L 4130  283 -7340 -1553 13.8X  NB   >50X  
K47A,Q72L 339 35 -8821 -267 1.6X  763  35 -8341 -689 3.2X  
A48G,Q72L 945  6 1 -8214 -874 4.4X  297  18 -8899 -131 1.2X  
D49A,Q72L 2330  349 -7680 -1353 10.8X  175  5 -9213 +183 0.7X  
D49E,Q72L 369  25 -8771 -317 1.7X  NB   >50X  
S50A,Q72L 140  29 -9345 +257 0.6X  990  79 -8186 -844 4.2X  
Y51A,Q72L NB   >50X  NB   >50X  
R52A,Q72L 682  112 -8407 -681 3.2 371  20 -8768 -262 1.6X  
L67A,Q72L 2680  141 -7597 -1491 10.3X  1040  120 -8157 -873 4.4X  
E73A,Q72L 1090  127 -8129 -959 5.0X  697 35 -8394 -636 2.9X  
D74A,Q72L 326  34 -8844 -244 1.6X  311 11 -8872 -158 1.3X  
Y75A,Q72L 544  15 -8541 -547 2.5X  413  35 -8704 -326 1.7X  
A77R,Q72L 585  50 -8498 -590 2.7X  203  11 -9125 +95 - 
I78A, Q72L 724  55 -8372 -716 3.4X  206  11 -9116 +86 - 
N81A,Q72L 696  52 -8395 -693 3.2X  491  48 -8602 -428 2.1X  
Y82A,Q72L 12080  3300 -3377 -5711 55X  230  18 -9051 +21 - 
R84A,Q72L 2320  89 -7682 -1496 10.7X  501  21 -8590 -440 2.1X  
a Equilibrium binding constants were determined in SPAs as described in the Materials and methods. Kd values are quoted 
with the standard errors from curve fitting  
b Kd values of greater than 1000 nM (1M) are based on data where it was not possible to achieve high enough 
concentrations to obtain a full binding curve. As such Kd values are subject to errors. 
c NB (no binding) denotes data that could not be fitted to the binding isotherm 
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Table 3: The affinities of RLIP76 RBD mutants for Ral isoforms
a
 
 RalA RalB 
RLIP76 RBD Kd (nM) 
 
G (cal/mol) G (cal/mol) Fold 
Change 
Kd (nM) 
 
G (cal/mol) G (cal/mol) Fold 
Change
C411S (wt) 185 ± 5 -9180 - - 261 ± 17 -8976 - - 
L409A,C411S 1880 ± 297b -7807 -1373 10.0X  4300 ± 1400 -7317 -1659 16.5X  
L412A,C411S 774 ± 123 -8332 -848 4.2X  228 ± 24 -9056 - - 
H413A,C411S NBc   >69X  NB   > 16X  
L416A,C411S 1700 ± 309 -7866 -1314 9.2X  1240 ± 147 -8053 -923 4.7X  
Q417A,C411S 126 ± 27 -9407 - - 99 ± 22 -9550 +574 2.2X  
K421A,C411S 433 ± 37 -8676 -504 2.3X  441 ± 30 -8665 -311 0.6X  
E426A,C411S 437 ± 131 -8671 -509 2.4X  670 ± 33 -8418 -558 2.6X  
E427A,C411S 452 ± 45 -8651 -529 2.4X  618 ± 39 -8465 -511 2.4X  
L429A,C411S 1030 ± 308 -8163 -1017 5.6X  5940 ± 928 -3588 -5388 22.8X  
W430A,C411S NB   >69X  NB   > 16X  
Q433A,C411S 216 ± 43 -9088 - - 197 ± 20 -9142 - - 
R434A,C411S NB   >69X  678 ± 77 -8411 -565 2.6X  
T437A,C411S NB   >69X  NB   > 16X  
K440A,C411S 1590 ± 410 -7906 -1274 8.6X  2300 ± 450 -7687 -1289 8.8X  
a Equilibrium binding constants were determined in SPAs as described in the Materials and methods. Kd values are quoted with the standard errors from curve 
fitting  
b Kd values of greater than 1000 nM (1M) are based on data where it was not possible to achieve high enough concentrations to obtain a full binding curve. As 
such Kd values are subject to errors. 
c NB (no binding) denotes data that could not be fitted to the binding isotherm 
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Figure 1: SPA binding data for full-length RalA, truncated RalA and truncated RalB with 
the RLIP76 RBD and the Sec5 RBD. The indicated concentration of [
3
H]GTP-labelled G protein 
was incubated with either His-tagged RLIP76 RBD or GST-tagged Sec5 RBD, as appropriate, in 
each SPA. The SPA signal was corrected by subtraction of the background signal from parallel 
measurements in which the effector protein was omitted. The effect of the concentration of G 
protein on this corrected SPA signal was fitted to a binding isotherm to give an apparent Kd value 
and the signal at saturating G protein concentrations. The data and curve fits are displayed as a 
percentage of this maximal signal: (A) binding isotherms of full-length and truncated RalA and 
truncated RalB with RLIP76 RBD, (B) binding isotherms of full-length and truncated RalA and 
truncated RalB with Sec5 RBD.  
Figure 2: SPA binding data for truncated RalB and mutant variants with the RLIP76 RBD 
and the Sec5 RBD. The indicated concentration of [
3
H]GTP-labelled G protein was incubated 
with either His-tagged RLIP76 RBD or GST-tagged Sec5 RBD, as appropriate, in each SPA. The 
SPA signal was corrected by subtraction of the background signal from parallel measurements in 
which the effector protein was omitted. The effect of the concentration of G protein on this 
corrected SPA signal was fitted to a binding isotherm to give an apparent Kd value and the signal at 
saturating G protein concentrations. The data and curve fits are displayed as a percentage of this 
maximal signal: (A) binding isotherms of truncated RalB and mutants with the RLIP76 RBD, (B) 
binding isotherms of truncated RalB and mutants with the Sec5 RBD. 
 
Figure 3: SPA binding data for the RLIP RBD and mutant variants with truncated RalA and 
RalB. The indicated concentration of [
3
H]GTP-labelled G protein was incubated with the 
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appropriate His-tagged RLIP76 RBD variant in each SPA. The SPA signal was corrected by 
subtraction of the background signal from parallel measurements in which the effector protein was 
omitted. The effect of the concentration of G protein on this corrected SPA signal was fitted to a 
binding isotherm to give an apparent Kd value and the signal at saturating G protein concentrations. 
The data and curve fits are displayed as a percentage of this maximal signal: (A) binding isotherms 
of the RLIP76 RBD variants with truncated RalB, (B) binding isotherms of the RLIP76 RBD 
variants with truncated RalA. 
 
Figure 4: Structural details of the RalB-RLIP76 and RalB-Sec5 interfaces. 
A. Residues whose mutation to Ala affects binding to RLIP76. RalB is shown in a blue ribbon 
representation, overlaid with a semi-transparent blue surface. Relevant residues are coloured as 
follows: red, more than 10-fold weaker affinity; orange, 5 to 10-fold weaker affinity; yellow, 3 to 
5-fold weaker affinity. Switch 1 encompasses residues 40-50 and switch 2 encompasses residues 
70-84, as assigned by comparing the structures in PDB entries 1U8Y and 1U90
37
.  
B. Residues whose mutation to Ala affects binding to Sec5. The colours are the as the same as in 
A.  
C. The structure of the RalB-RLIP76 complex (PDB 2KWI) is shown with the residues whose 
mutation affects RLIP binding shown as sticks. RalB is blue, RLIP76 is dark pink. The mutated 
residues are shown in the same colour scheme as in A. 
D. A model of RalB-Sec5 is shown, constructed using Modeller
38
 based on PDB 1UAD, with the 
residues that affect Sec5 binding shown as sticks. RalB is blue and Sec5 is pale pink. The mutated 
residues are shown in the same colour scheme as in A. 
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Figure 5: Hotspots on RLIP76 for binding to Ral proteins 
A. Residues whose mutation to Ala disrupts binding to RalA. Relevant residues are coloured as 
follows: red, more than 10-fold weaker affinity; orange, 5 to 10-fold weaker affinity; yellow, 3 to 
5-fold weaker affinity.    
B. Residues whose mutation to Ala disrupts binding to RalB. The colour scheme for residues is the 
same as in A. 
C. The two residues whose mutation has drastically different effects on RalA and RalB binding to 
RLIP76. RalB is blue and RLIP76 is dark pink. Leu429 and Arg434 are shown in green and the 
residues that they contact in RalB are shown in yellow. The positions of conservative changes 
between RalA and RalB are shown as cyan spheres: these include Asp/Glu, Lys/Arg, Val/Ile/Leu 
or Asn/Gln exchanges only. The positions of less conservative changes between the two proteins 
are shown as orange spheres. Finally, the position of a single amino acid insertion (Ala116) in 
RalB is shown as a red sphere. 
 
 
